'Expanded access' presentation slideshows

expanded access to investigational drugs; background & issues

WELCOME. expanded access to investigational drugs; background & issues. Diane e. Dorman, National organization for rare disorders. PANELISTS. Sascha Haverfield, Ph.D. Vice President for Scientific Regulatory Affairs, PhRMA Richard Klein, Director, FDA Patient Liaison Program

969 views • 56 slides

Middleware Activities Update

Middleware Activities Update. Internet2 Membership, with coordination provided by Internet2 et al presentation by Renee Woodten Frost Internet2 and the University of Michigan. Internet2 New Initiatives. A brief introduction to new initiatives launched at the Internet2 Fall Member Meeting:

452 views • 45 slides

Session 2 Expanded Clinical Trials Registry Deborah A. Zarin, M.D.

471 views • 35 slides

Richard Klein Office of Health and Constituent Affairs Food and Drug Administration

Expanded Access Programs for Drugs and Biologics _________________________________________________________. Richard Klein Office of Health and Constituent Affairs Food and Drug Administration. February 27, 2014. What is Expanded Access?. also called Treatment Use, Compassionate Use.

379 views • 27 slides

Richard Klein Office of Health and Constituent Affairs Food and Drug Administration

Expanded Access Programs for Drugs and Biologics _________________________________________________________. Richard Klein Office of Health and Constituent Affairs Food and Drug Administration. February 27, 2014. What is Expanded Access?. also called Treatment Use, Compassionate Use.

273 views • 27 slides

Designing Shock Protection for Vulnerable Households: A How-to Guide

Designing Shock Protection for Vulnerable Households: A How-to Guide. Jonathan Zinman Dartmouth College. BASIS CRSP Policy Conference Impact Evaluation of Innovations in Rural Finance June 13, 2006. Overview of Talk. What are shocks?

311 views • 25 slides

Single Patient Use of Investigational Anticancer Agents:

Single Patient Use of Investigational Anticancer Agents:. An Industry Perspective Gerard T. Kennealey, MD Vice President, Clinical Research, Oncology AstraZeneca Pharmaceuticals December 14, 2000. Rising Public Expectations Make Earlier Access Necessary.

301 views • 19 slides

NCRP Promotes Philanthropy That:

242 views • 16 slides

275 views • 14 slides

Health Care Reform

Health Care Reform. Including migrants and other vulnerable populations - Al Hernandez Santana, LCHC. Presenter Disclosures. Al Hernandez Santana. No relationships to disclose.

239 views • 13 slides

Industry Perspective: Expanded Access Programs

Industry Perspective: Expanded Access Programs. Barbara Klencke, M. D. Senior Vice President, Development Onyx Pharmaceuticals, an Amgen Subsidiary. Disclaimer.

165 views • 8 slides

The Right Care at the Right Time: Are Retail Clinics Meeting a Need?

The Right Care at the Right Time: Are Retail Clinics Meeting a Need?. Alliance for Health Reform Briefing | Washington, D.C. | June 18, 2012 Manish Oza, M.D. Regional Vice President and Medical Director WellPoint, Inc. Program Design. Viral Disruptive Innovative

179 views • 5 slides